|Bid||0.00 x 2900|
|Ask||0.00 x 900|
|Day's Range||8.48 - 8.88|
|52 Week Range||7.42 - 44.00|
|Beta (3Y Monthly)||2.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.60|
Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 35,366 shares of the company’s common stock, at a per share exercise price of $9.56, the closing trading price on January 8, 2019, and restricted stock units to acquire 5,910 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.
Adamas Pharmaceuticals, Inc. (ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today outlined key business priorities for 2019 and provided preliminary 2018 sales results for GOCOVRI™ (amantadine) extended release capsules. GOCOVRI is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy and only medication clinically proven to reduce both dyskinesia and OFF in that population.
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit 52-week highs Tuesday. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 18) Accelerate ...
The USPTO has now issued a total of 14 patents from three separate patent families in the GOCOVRI patent portfolio, which now has patents expiring from 2025 to 2034. The ‘971 patent will be listed in the U.S. Food and Drug Administration’s (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. GOCOVRI (amantadine) extended release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds and investors’ positions as of the end of the third quarter. You can find write-ups about an individual hedge fund’s trades on numerous financial news websites. […]
EMERYVILLE, Calif., Nov. 09, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central.
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The Emeryville, California-based company said it had a loss of $1.22 per share. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was ...
GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Merck & Co., Inc. (NYSE: MRK )(announced FDA approval ...
Adamas Pharmaceuticals, Inc. (ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that it will report third quarter 2018 financial results on Thursday, November 1, 2018, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. The conference call can be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers.
LONDON/HOUSTON Oct 24 (Reuters) - The Chinese government is limiting domestic production of rare earth minerals in the second half of the year, a move likely to crimp international exports and send prices for the critical materials soaring, according to data from Adamas Intelligence. China is by far the world's largest producer and consumer of rare earths, a group of 17 elements used to make electric vehicles and consumer electronics. The move is already forcing manufacturers to scour the globe for alternative supplies.
Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS): Adamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The US$543m market-cap posted a loss in its most recent financial year of -US$89m Read More...
In the second quarter, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in the second quarter of 2017. In the first half, Supernus Pharmaceuticals generated net revenues of $190.0 million compared to $133.4 million in the first half of 2017.
On September 11, Supernus Pharmaceuticals (SUPN) stock closed at $48.80, up 1.99% from its closing price of $47.85 on September 10. The company’s September 11 stock price was 26.0% below its 52-week high of $61.25 on June 29. Supernus Pharmaceuticals hit its 52-week low of $33.30 on November 7, 2017.